Depression and Anxiety Trial, Recruiting NCT07082998 Sponsor: Massachusetts General Hospital Condition: Depression and Anxiety
Back to Depression And Anxiety

Depression and Anxiety Trial, Recruiting

NCT07082998
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 65 years old
  • You are able to give your consent to participate in the study
  • You can read and communicate in English
  • You have scored above 10 on a standard depression questionnaire (PHQ-9), meaning you have at least moderate symptoms of depression
  • You have completed a required waiver form for the community partners involved in the study before enrolling
  • If you could become pregnant, you are willing to use an acceptable form of birth control during the study
  • If you are already taking psychiatric medications or attending therapy, you are willing to keep these the same throughout the study
  • You have access to a smartphone, iPad, or similar device that can run a mindfulness app
  • You are able to travel to a location called "Breathe" in Harvard Square, and to at least one "Restore" location (in Hingham, Somerville, Dedham, Newton, or Lynnfield)

Who may not be able to join:

  • You are currently pregnant or planning to become pregnant during the study
  • You are currently breastfeeding
  • You are currently having thoughts of suicide (as identified through standard screening tools used by the study team)
  • You have had an active eating disorder or substance use disorder within the past 12 months (as assessed by a standard screening interview)
  • Your primary mental health condition is OCD (Obsessive-Compulsive Disorder) or PTSD (Post-Traumatic Stress Disorder), as identified by a standard screening interview
  • You have a history of bipolar disorder or psychotic disorders, as identified by a standard screening interview
  • Your depression score dropped by 25% or more between your first screening and the start of the study
  • You are currently under the influence of, or going through withdrawal from, drugs or alcohol
  • A urine drug test shows the presence of illegal drugs or other medications that disqualify you from the study (unclear cases will be reviewed individually by the study lead)
  • You have had a bone fracture or joint surgery in the past 6 months
  • You have difficulty walking or cannot walk freely
  • You have a serious or unstable health condition identified through a standard physical activity health questionnaire (PAR-Q+), unless your own doctor has approved your participation
  • You do not have a healthcare provider you could contact if needed — such as a primary care doctor, counselor, psychiatrist, nurse practitioner, or regular clinic
  • You have attended more than 6 heated yoga classes in the past 3 months
  • You have used a sauna more than 6 times in the past 3 months
  • You have used a mindfulness app more than 6 times in the past 3 months
  • You take certain medications that increase the risk of dehydration or have certain health devices — for example, lithium, antipsychotics, insulin, diuretics, barbiturates, beta-blockers, anticholinergics, or if you have a pacemaker or hemophilia (confirm with trial site)
  • You started an antidepressant or psychiatric medication less than 8 weeks ago, or had a dose change less than 4 weeks ago
  • You started a new course of therapy (psychotherapy) within the past 3 months
  • You have been admitted to a psychiatric hospital within the past year
  • You have a neurological condition that could affect your ability to participate safely
  • You are currently receiving ketamine treatment, electroconvulsive therapy (ECT), or transcranial magnetic stimulation (TMS)
  • You are unable to follow the study procedures, such as travelling to the heated yoga or sauna locations
  • The study's Principal Investigator has determined that your participation would not be safe or could affect the quality of the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Maren B Nyer, PhD, Massachusetts General Hospital

Phone: 617-726-8895

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
12 September 2025
Est. completion
31 July 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Patient Health Questionnaire (PHQ-9)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov